Eugia Pharma receives USFDA Approval for Bivalirudin Injection!
Published: July 31, 2018
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bivalirudin injection, 250 mg/vial. The approved ANDA is a generic equivalent to the reference listed drug (RLD) product Angiomax® Injection of The Medicines Company.
The estimated market size Bivalirudin injection is US$ 101 million for the twelve months ending May 2018 according to IQVIA.
To view the complete press release, click here: PR USFDA FA – Bivalarudin Injection